Transbronchial Ablation for Peripheral Lung Tumor

Not Applicable

• Conditions: Lung Cancer
• Interventions: Procedure: Microwave ablation; Procedure: Radiofrequency ablation

• Registration Number: NCT02972177
• Lead Sponsor: Shanghai Chest Hospital

Brief Summary

The objective of the study was to evaluate the efficacy and safety of navigation bronchoscopy guided transbronchial ablation for the treatment of inoperable peripheral lung tumor.

Detailed Description

The study is aimed to evaluate the efficacy and safety of navigation bronchoscopy guided transbronchial ablation for treating inoperable malignant lung tumor. The study is designed as a single-center prospective trial. The participating centers are Department of pulmonary medicine and endoscopy, Shanghai Chest Hospital,Shanghai Jiao Tong University, China. Patients are divided into two groups, including radiofrequency ablation group and microwave ablation group. Sixty patients are expected to be enrolled into the study with 30 patients in each group.

Study Timeline

• Study First Submitted: 2016-11-12
• Study First Submitted QC: 2016-11-21
• Study First Posted: 2016-11-23
• Study Start: 2018-02-07
• Status Verified: 2020-02
• Last Update Submitted: 2020-02-16
• Last Update Posted: 2020-02-18
• Primary Completion: 2020-12
• Study Completion: 2021-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Patients older than 18 year-old.
2. Patients meeting one of the following criteria: 1) patients discovered with peripheral lung lesions that have demonstrated to be lung cancer by pathology with the clinical stage no later than IIA. 2) recurrent or progressive single lesion or solitary intrapulmonary metastasis after surgery, radiotherapy, chemotherapy or other treatment.3) multiple primary lung cancer with the number of tumors no more than 5 and no metastasis. 4) pulmonary metastases with effective treatment of primary disease, the number of metastases no more than 5 and no other metastasis.
3. Chest CT shows the length-diameter of the tumor is more than 8mm and no more than 50mm.
4. Patients are unsuitable for surgery assessed by multidisciplinary team and agree to the primary treatment of ablation.
5. Patients have good compliance and sign the informed consent.

Read More

Exclusion Criteria

1. Patients cannot receive bronchoscopy for the severe cardiopulmonary dysfunction and other indications.
2. Patients have contraindications of general anesthesia.
3. Chest CT or bronchoscopy shows that guided and treatment instruments cannot reach the peripheral lung lesion.
4. There are large blood vessels or important structures adjacent to peripheral lung lesion.
5. Researchers consider the patient do not fit for the study due to other reasons.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Microwave ablation group	Microwave ablation	Patients with inoperable peripheral lung tumor will be performed transbronchial microwave ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
Radiofrequency ablation group	Radiofrequency ablation	Patients with inoperable peripheral lung tumor will be performed transbronchial radiofrequency ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.

Primary Outcome Measures

Name	Time	Method
Local control rate	Three months after ablation	Local control rate was defined as the proportion of the complete ablation and incomplete ablation of the tumor.

Secondary Outcome Measures

Name	Time	Method
Progression-free survival (PFS)	From the time of treatment to the time of disease progression or death, assessed up to 1 year	PFS was defined from the first day after ablation to progression of target lesions and/or appearance of new lesions or death.
Overall survival（OS）	From the time of treatment to the time of the patient death, assessed up to 3 years	Overall survival（OS) is evaluated after the treatment of ablation until the patient death.
Cancer-specific survival	From the time of treatment to the time of the patient death, assessed up to 3 years	The cause of death is related to the patient's underlying malignancy.

Trial Locations

Locations (1)

Shanghai Chest Hospital; 🇨🇳 Shanghai, China